Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 6, 2011, Pages 608-613

  Kim, William Y ^a   Whang, Young E ^a   Pruthi, Raj S ^a   Baggstrom, Maria Q ^a,b   Rathmell, W Kimryn ^a   Rosenman, Julian G ^a   Wallen, Eric M ^a   Goyal, Lav K ^c   Grigson, Gayle ^d   Watkins, Catharine ^d   Godley, Paul A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOLY CROSS HOSPITAL   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Docetaxel; Estramustine; High risk prostate cancer; Neoadjuvant; Prostatectomy; Radiotherapy

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; WARFARIN;

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RISK; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; MALE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; TAXOIDS; TREATMENT OUTCOME;

EID: 81055124945     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.09.012     Document Type: Article

References (29)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2008. CA Cancer J Clin 2008, 58:71-96.
2. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
3. Catalona W.J., Smith D.S. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 1998, 160:2428-2434.
4. Kupelian P., Katcher J., Levin H., et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996, 48:249-260.
5. Kupelian P.A., Katcher J., Levin H.S., et al. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997, 37:1043-1052.
6. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997, 24:395-406.
7. Aus G., Abrahamsson P.A., Ahlgren G., et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial. BJU Int 2002, 90:561-566.
8. Hurtado-coll A., Goldenberg S.L., Klotz L., et al. Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: The Canadian experience. Urology 2002, 60:45-51. Discussion 51.
9. Soloway M.S., Pareek K., Sharifi R., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: Five-year results. J Urol 2002, 167:112-116.
10. Goldenberg S.L., Klotz L.H., Srigley J., et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 1996, 156:873-877.
11. Schulman C.C., Debruyne F.M., Forster G., et al. Four-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000, 38:706-713.
12. Labrie F., Dupont A., Cusan L., et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial. Clin Invest Med 1993, 16:499-509.
13. Febbo P.G., Richie J.P., George D.J., et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005, 11:5233-5240.
14. Garzotto M., Myrthue A., Higano C.S., et al. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006, 24:254-259.
15. Dreicer R., Magi-Galluzzi C., Zhou M., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004, 63:1138-1142.
16. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 2002, 360:103-106.
17. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295-300.
18. Roach M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003, 21:1904-1911.
19. D'Amico A.V., Manola J., Loffredo M., et al. Six-month androgen suppression plus radiation therapy versus radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004, 292:821-827.
20. Craft N., Chhor C., Tran C., et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999, 59:5030-5036.
21. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
22. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
23. Clark P.E., Peereboom D.M., Dreicer R., et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001, 57:281-285.
24. Magi-Galluzzi C., Zhou M., Reuther A.M., et al. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: A clinicopathologic study. Cancer 2007, 110:1248-1254.
25. Prayer-Galetti T., Sacco E., Pagano F., et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 2007, 100:274-280.
26. Hussain M., Smith D.C., El-Rayes B.F., et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 2003, 61:774-780.
27. Chi K.N., Chin J.L., Winquist E., et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008, 180:565-570. Discussion 570.
28. Konety B.R., Eastham J.A., Reuter V.E., et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: Results of a phase I/II study. J Urol 2004, 171:709-713.
29. Pettaway C.A., Pisters L.L., Troncoso P., et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 2000, 18:1050-1057.